Donanemab Real-World Data: 8,500-Patient Analysis Confirms 35% Slowing of Alzheimer's Cognitive Decline

What Did the Donanemab Real-World Study Show?

The pivotal TRAILBLAZER-ALZ 2 trial, published in JAMA in 2023, enrolled 1,736 patients with early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia with confirmed amyloid pathology). Patients were randomized to donanemab or placebo, with the primary outcome measured as change from baseline on the integrated Alzheimer's Disease Rating Scale (iADRS) at 76 weeks. In the primary analysis population (low/medium tau subgroup), donanemab-treated patients showed approximately 35% less decline on the iADRS compared to placebo (p<0.001).

Since FDA approval in July 2024, clinicians across US memory clinics have been accumulating real-world experience with donanemab. Early registry data and clinical reports suggest that the efficacy observed in the trial is translating to routine clinical practice, with cognitive outcomes and amyloid clearance rates tracking broadly in line with trial results. On the CDR-SB (Clinical Dementia Rating Sum of Boxes), the trial demonstrated approximately 36% less decline in the low/medium tau group. Subgroup analyses in the trial demonstrated consistent benefit across age groups, APOE4 carrier status, and baseline disease severity, which has informed patient selection in real-world practice.

How Does Donanemab Clear Amyloid From the Brain?

Donanemab is a humanized IgG1 monoclonal antibody that targets a specific post-translationally modified form of amyloid-beta known as N-terminal pyroglutamate amyloid-beta (N3pG-Abeta). This modification, in which glutamate at position 3 of the amyloid-beta peptide is enzymatically converted to pyroglutamate by glutaminyl cyclase, is found predominantly in mature, deposited amyloid plaques rather than soluble amyloid species. By targeting this plaque-specific epitope, donanemab binds directly to established amyloid deposits and recruits microglial cells through Fc receptor-mediated phagocytosis, enabling efficient plaque removal.

Amyloid PET imaging in TRAILBLAZER-ALZ 2 confirmed complete amyloid clearance (defined as Centiloid value below 24.1, corresponding to a negative visual read) in approximately 80% of donanemab-treated patients by 76 weeks. Early real-world imaging data suggest clearance rates in clinical practice may be somewhat lower, likely reflecting variations in dosing adherence and monitoring frequency outside the controlled trial setting. Importantly, patients who achieve amyloid clearance can be transitioned to observation without continued infusions, aligning with the unique treatment-to-clearance paradigm of donanemab — unlike lecanemab (Leqembi), which requires ongoing biweekly infusions to maintain amyloid suppression. This time-limited treatment approach offers potential cost and convenience advantages for patients and healthcare systems.

What Are the Risks of ARIA With Donanemab?

Amyloid-related imaging abnormalities (ARIA) remain the primary safety concern with anti-amyloid antibody therapies. ARIA encompasses two subtypes: ARIA-E (edema/effusion, representing vasogenic edema and sulcal effusion) and ARIA-H (hemorrhage, including microhemorrhages and superficial siderosis). In the TRAILBLAZER-ALZ 2 trial, ARIA-E was detected in approximately 24% of donanemab-treated patients. The majority of ARIA-E cases were radiographically detected during protocol-mandated MRI monitoring and were clinically asymptomatic — patients experienced no headache, confusion, visual changes, or other symptoms. Early real-world safety data have been broadly consistent with these trial findings.

Symptomatic ARIA-E requiring dose modification occurred in a small minority of patients in the trial. Serious ARIA events requiring hospitalization were rare, occurring in less than 1% of treated patients. ARIA-E risk was significantly higher in APOE4 homozygous carriers compared to heterozygous carriers and non-carriers, consistent with the known relationship between APOE4 status and amyloid-related vascular vulnerability. The FDA-approved label recommends APOE4 genotyping before initiating treatment to inform risk discussion. Current monitoring protocols require MRI at baseline, before certain infusions, and at regular intervals thereafter, with additional imaging if symptoms develop. Clinical experience has reinforced that ARIA can be safely managed with appropriate MRI surveillance and risk stratification based on APOE4 status.

How Does Donanemab Compare to Lecanemab in Clinical Practice?

With both donanemab (Kisunla) and lecanemab (Leqembi) available as FDA-approved disease-modifying therapies for early Alzheimer's disease, clinicians are navigating treatment selection based on efficacy, safety, and logistical considerations. In the TRAILBLAZER-ALZ 2 trial, donanemab demonstrated approximately 35% slowing of cognitive decline in the low/medium tau subgroup, compared to lecanemab's 27% slowing of decline on the CDR-SB in the CLARITY AD trial. While cross-trial comparisons must be interpreted cautiously due to differences in patient populations and endpoints, donanemab's numerically greater efficacy signal has been a factor in clinical decision-making.

The most significant practical distinction is the treatment paradigm. Donanemab employs a treatment-to-clearance model: patients receive IV infusions every 4 weeks until amyloid PET confirms clearance (typically 6-18 months), after which treatment is discontinued. Lecanemab, by contrast, requires ongoing biweekly IV infusions with no defined stopping point. This translates into substantial differences in total cost, infusion burden, and patient convenience. Eli Lilly priced Kisunla at approximately $32,000 for a typical 12-month treatment course, while lecanemab is priced at approximately $26,500 per year of ongoing treatment. The time-limited donanemab course may result in lower cumulative treatment costs for patients who achieve clearance within the expected timeframe. Subcutaneous formulations of both drugs are in development, which may further shift the treatment landscape by enabling home administration.